rheumatoid arthritis

ICER says AbbVie’s Rinvoq for RA may be cost-effective but still questions the value of JAK class
ICER says AbbVie’s Rinvoq for RA may be cost-effective but still questions the value of JAK class
Fierce Pharma
ICER
AbbVie
Rinvoq
rheumatoid arthritis
JAK inhibitors
Flag link:
Gilead, Galapagos share 52-week update on filgotinib
Gilead, Galapagos share 52-week update on filgotinib
Fierce Biotech
Gilead Sciences
Galapagos
filgotinib
clinical trials
rheumatoid arthritis
Flag link:
ICER pulls report blasting ‘marginal’ RA drugs, citing need to rethink its approach
ICER pulls report blasting ‘marginal’ RA drugs, citing need to rethink its approach
Fierce Pharma
ICER
JAK inhibitors
rheumatoid arthritis
AbbVie
Rinvoq
Pfizer
Xeljanz
Incyte
olumiant
Flag link:
Rheumatoid Arthritis Drug May Help Repair Heart After Heart Attacks
Rheumatoid Arthritis Drug May Help Repair Heart After Heart Attacks
BioSpace
VentriGel
Ventrix
rheumatoid arthritis
heart attacks
Flag link:
Price, safety will test blockbuster billing for AbbVie's new arthritis drug
Price, safety will test blockbuster billing for AbbVie's new arthritis drug
Biopharma Dive
AbbVie
rheumatoid arthritis
drug pricing
Rinvoq
Flag link:
Rinvoq approval bolsters AbbVie's autoimmune portfolio
Rinvoq approval bolsters AbbVie's autoimmune portfolio
BioCentury
AbbVie
FDA
Rinvoq
Upadacitinib
rheumatoid arthritis
Flag link:
AbbVie's psoriasis launch Skyrizi hitting stride ahead of FDA's decision on upadacitinib
AbbVie's psoriasis launch Skyrizi hitting stride ahead of FDA's decision on upadacitinib
Fierce Pharma
AbbVie
Humira
biosimilars
Europe
psoriasis
rheumatoid arthritis
Skyrizi
Flag link:
GSK begins phase 3 trial for otilimab in patients with rheumatoid arthritis
GSK begins phase 3 trial for otilimab in patients with rheumatoid arthritis
Pharmaceutical Business Review
GSK
clinical trials
rheumatoid arthritis
otilimab
monoclonal antibodies
Flag link:
Watch out AbbVie: Gilead is fast on your heels at the FDA with rival JAK inhibitor filgotinib
Watch out AbbVie: Gilead is fast on your heels at the FDA with rival JAK inhibitor filgotinib
Endpoints
Gilead Sciences
AbbVie
FDA
JAK inhibitors
filgotinib
Upadacitinib
rheumatoid arthritis
Flag link:
3 Drugs Under FDA Review With Blockbuster Potential
3 Drugs Under FDA Review With Blockbuster Potential
Motley Fool
AbbVie
Upadacitinib
rheumatoid arthritis
Novartis
brolucizumab
wet age-related macular degeneration
Celgene
ozanimod
relapsing multiple sclerosis
Flag link:
Pfizer announces results from XELJANZ XR ORAL Shift study
Pfizer announces results from XELJANZ XR ORAL Shift study
Pharmaceutical Business Review
Pfizer
Xeljanz
clinical trials
rheumatoid arthritis
Flag link:
Look here, FDA: Eli Lilly touts Olumiant safety data for unapproved high dose
Look here, FDA: Eli Lilly touts Olumiant safety data for unapproved high dose
Fierce Pharma
Eli Lilly
Incyte
olumiant
safety data
Humira
rheumatoid arthritis
Flag link:
4 Blockbuster Drug Launches to Watch in 2019
4 Blockbuster Drug Launches to Watch in 2019
Motley Fool
drug launches
AbbVie
Alexion Pharmaceuticals
Aimmune Therapeutics
Skyrizi
psoriasis
Upadacitinib
rheumatoid arthritis
Ultomiris
PNH
AR101
peanut allergy
Flag link:
EMA sounds its own safety alarm for Pfizer blockbuster, but they’re also not forcing a limit on dosing — yet
EMA sounds its own safety alarm for Pfizer blockbuster, but they’re also not forcing a limit on dosing — yet
Endpoints
Pfizer
Xeljanz
Europe
EMA
rheumatoid arthritis
Flag link:
2 Biotech Stocks With Major Incoming Catalysts
2 Biotech Stocks With Major Incoming Catalysts
Yahoo/Motley Fool
Axsome Therapeutics
AXS-05
depression
Galapagos
filgotinib
Gilead Sciences
rheumatoid arthritis
Flag link:
Pfizer drops higher dose treatment arm in Xeljanz post-marketing study due to safety issues
Pfizer drops higher dose treatment arm in Xeljanz post-marketing study due to safety issues
CP Wire
Pfizer
Xeljanz
post-marketing studies
FDA
rheumatoid arthritis
ulcerative colitis
Flag link:
Pfizer drops higher dose treatment arm in Xeljanz post-marketing study due to safety issues
Pfizer
Xeljanz
post-marketing studies
FDA
rheumatoid arthritis
ulcerative colitis
Flag link:
AbbVie’s JAK inhibitor upadacitinib gets Priority Review
AbbVie’s JAK inhibitor upadacitinib gets Priority Review
Pharmaforum
AbbVie
upadacatinib
FDA
priority review
rheumatoid arthritis
Humira
Flag link:
Could Gilead and Galapagos' JAK inhibitor lead the class? Wall Street thinks it has a chance.
Could Gilead and Galapagos' JAK inhibitor lead the class? Wall Street thinks it has a chance.
Biopharma Dive
Gilead Sciences
Galapagos
JAK inhibitors
rheumatoid arthritis
filgotinib
Flag link:
Generic arthritis drug comes up short against inflammation in heart disease
Generic arthritis drug comes up short against inflammation in heart disease
Stat
generics
rheumatoid arthritis
methotrexate
Flag link:

Pages